Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Visa (V) Dips More Than Broader Market: What You Should Know

View original at finance.yahoo.com
Visa (V) Dips More Than Broader Market: What You Should Know In the latest close session, Visa (V) was down 3.38% at $295.19. The stock's change was less than the S&P 500's daily loss of 1.67%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Full year projections are earnings of $12.84 per share and revenue of $44.5 billion, representing changes of +11.94% and +11.26% respectively from prior year

    60% confidence

  • Visa is predicted to post an EPS of $3.09, indicating a 11.96% growth compared to the equivalent quarter last year

    60% confidence

  • Visa is trading at a premium compared to its industry based on Forward P/E ratio

    60% confidence

  • Zacks Rank #1 stocks have yielded an average annual return of +25% since 1988

    60% confidence

  • Positive alterations in estimates signify analyst optimism regarding the business and profitability

    60% confidence

  • Quarterly revenue consensus estimate is $10.7 billion, up 11.51% from the year-ago period

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Visa (V) Dips More Than Broader Market: What You Should Know — Source | Via News | ViaNews EU